Today’s cell therapy treatments are often made at a small-scale, include manual preparation, and are usually produced for use in a clinical trial. Researchers spend days processing cellular material, monitoring its growth during the expansion phase, and preparing it for re-administration to the patient. With autologous treatments, this process must be completed for every patient to create their unique living drug.
In return, cell therapy offers life-changing outcomes. For example, terminal acute lymphoblastic leukemia patients achieved complete remission in 90% of cases during one cell therapy trial. But what if it were possible to get those results on a much broader scale? Automation may hold the key to making this happen.